CytRx, a biopharmaceutical research and development company, has announced plans to initiate a Phase II clinical trial for its drug candidate INNO-206 to treat patients who suffer from advanced, treatment-resistant soft tissue sarcoma.
Global Cancer Consortium
ImmunoGen Signs 2nd Licensing Deal with Amgen
ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.
Controversy Over New Breast Cancer Screening Guidelines
The U.S. Preventive Services Task Force recommended this week that women should begin getting routine mammograms at the age of 50 instead of the previously recommended age of 40.
Burrill Report: Biotech Innovation Gets the Cash
If the past week is any indication, big pharma is showing that it is willing to pay for biotech innovation.
ProtoxPresents Data, Awaits Key Results for PRX302
Protox Therapeutics applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer.
Bioniche Receives $6M Milestone Payment for Bladder Cancer Drug
Bioniche Life Sciences has received its first milestone payment of $6 million from Endo Pharmaceuticals for its experimental bladder cancer drug.
Guided Therapeutics Study Reveals Cervical Screening Shortcomings
A clinical trial by Guided Therapeutics (GT), a biotechnology company specializing in women’s health, found that current screening methods for cervical disease missed the disease nearly a third of the time.
GenVec Receives Orphan Drug Designation, $22M Development Deal
GenVec’s experimental drug to treat pancreatic cancer has been granted orphan drug status by the U.S. Food and Drug Administration.
